AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival
By Kelly Cloonan
Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said.
AbbVie and Genmab said Friday the trial results also showed improvement in patients' complete response rate, duration of response and time to next treatment.
The study didn't demonstrate a statistically significant improvement in overall survival, however, the companies said.
The study enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant.
Further analysis of the results is continuing, the companies said.
Genmab and AbbVie plan to engage with global regulatory authorities to discuss next steps. The data will also be submitted for presentation at a future medical meeting, they said.
"The results from this global trial contribute to the growing body of evidence supporting epcoritamab," Genmab's Chief Executive Jan van de Winkel said.
Epcoritamab has previously received regulatory approval for certain lymphoma indications in more than 65 countries.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
January 16, 2026 14:25 ET (19:25 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States